Almquist R G, Jennings-White C, Chao W R, Steeger T, Wheeler K, Rogers J, Mitoma C
J Med Chem. 1985 Aug;28(8):1062-6. doi: 10.1021/jm00146a014.
Two pentapeptide analogues of the ketomethylene-containing angiotensin converting enzyme (ACE) inhibitor 5(S)-benzamido-4-oxo-6-phenylhexanoyl-L-proline (1) were synthesized and evaluated as ACE inhibitors and antihypertensive agents. Compounds 14 and 15 were very potent ACE inhibitors with I50 values of 7.0 and 3.0 nM, respectively, compared to an I50 value of 70 nM for 1. Neither 14 nor 15 showed significant blood pressure lowering activity in renal hypertensive rats. Investigations conducted on a tritiated analogue of 14 showed that 70% of an oral dose of this compound is absorbed but is rapidly excreted from the blood with a half life of 24 min. Thin-layer chromatography of bile and urine contents in rats given tritiated 14 orally showed that it is excreted in greater than 90% unchanged form. This implies that a ketomethylene linkage can stabilize peptide amide linkages adjacent to it to peptidase degradation.
合成了含酮亚甲基的血管紧张素转换酶(ACE)抑制剂5(S)-苯甲酰胺基-4-氧代-6-苯基己酰基-L-脯氨酸(1)的两种五肽类似物,并将其作为ACE抑制剂和抗高血压药物进行了评估。与1的I50值70 nM相比,化合物14和15是非常有效的ACE抑制剂,I50值分别为7.0和3.0 nM。在肾性高血压大鼠中,14和15均未显示出明显的降压活性。对14的氚代类似物进行的研究表明,该化合物口服剂量的70%被吸收,但从血液中迅速排泄,半衰期为24分钟。对口服氚代14的大鼠胆汁和尿液成分进行的薄层色谱分析表明,它以大于90%的未变化形式排泄。这意味着酮亚甲基键可以稳定与其相邻的肽酰胺键以抵抗肽酶降解。